StocksMedium•12 November 2026•
1 min read
Kyverna Therapeutics Completes miv-cel BLA Submission and Reports Q3 Results
Key Facts
1Kyverna Therapeutics completed the BLA submission for miv-cel in Stiff Person Syndrome (SPS) with a request for priority review.
2The company reported its Q3 2026 financial results while advancing commercial readiness for the potential U.S. launch of miv-cel.
Kyverna Therapeutics completed the Biologics License Application (BLA) submission for miv-cel in Stiff Person Syndrome (SPS) with a request for priority review. GlobeNewswire reported that the company also announced its Q3 2026 financial results while advancing commercial readiness for the potential U.S. launch of the therapy.
KYTX closed at $5.12 on November 11, 2026, with the stock trading between a low of $5.02 and a high of $5.23 during that session. These regulatory milestones occur as the company focuses on commercial preparation and its goal to transform the treatment paradigm for autoimmune diseases using CAR-T technology.